Eletriptan Hydrobromide, CAS number 143322-58-1, is a medication indicated for the acute treatment of migraine with or without aura in adults. Known as Relpax, which is marketed by Pfizer, the patent expiration for Eletriptan Hydrobromide is on December 26, 2016 (Patent Use Code U – 876 – TREATMENT OF MIGRAINE WITH OR WITHOUT AURA). Available in 20 milligram and 40 milligram tablets, eletriptan hydrobromide has been shown to be more effectual with the higher dosage of 40 milligrams. Doses of 80 milligrams in trials were deemed efficacious, but led to a greater instance of adverse effects. The maximum recommended dose of eletriptan hydrobromide is 40 milligrams. Common side effects of eletriptan hydrobromide are dizziness, nausea, weakness, drowsiness, and pain or pressure sensations in the chest or throat.
The efficacy of eletriptan hydrobromide, or Relpax, for the acute treatment of migraines was evaluated in eight double-blind, placebo-controlled and randomized studies. All eight studies used 40 milligrams as a dosage amount, and seven studies evaluated an 80 milligram dose as well. In addition, two of the eight studies included a 20 milligram dose. These outpatient studies included adults, with only one study involving adolescents ages 11 to 17. The patients in the seven adult studies were mostly female, specifically 85 percent of patients. Caucasian patients were also the majority in these studies, with 94 percent of the patients being of this race. The mean age of patients was 40 years of age, although the patient age range was from age 18 to age 78. All of the patients in these studies were told to treat their headache if it was moderate or severe in nature. Some patients also experienced symptoms alongside their migraines, such as nausea, vomiting, photophobia and phonophobia. Patients were assessed two hours after their dosage of eletriptan hydrobromide, and up to 24 hours after their dose. Results from the seven adult studies revealed that the percentage of patients who achieved a headache response 2 hours after treatment with eletriptan hydrobromide was significantly greater when compared to patients who received a placebo. The study involving adolescents also indicated a positive response rate for patients who were dosed with eletriptan hydrobromide.
There are more than 37 million Americans who suffer from migraines. Approximately 3.2 million Americans have chronic migraine, which is defined as migraine or tension-type headaches 15 or more days a month. According to the World Health Organization, migraines are responsible for at least 1 percent of the total U.S. medical disability burden. These statistics are serious, and indicate an urgent need for research and development of medications to treat this disabling condition. LGM Pharma provides API Eletriptan Hydrobromide for research and development purposes. Clients can be assured of complete support from LGM Pharma throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.